Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Heron Therapeutics, Inc. - Common Stock (NQ:HRTX)

0.3645 +0.0328 (+9.89%)
Delayed Quote Updated: 1:21 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Heron Therapeutics, Inc. - Common Stock

News headline image
Heron Therapeutics Announces Second Quarter 2026 Financial Results
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
U.S. District Court Issues Decision Regarding CINVANTI® Patents
After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal 
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
From Heron Therapeutics, Inc.
Via GlobeNewswire
Heron Therapeutics Inc. (NASDAQ: HRTX) Near the Top of Equities by Percentage Gain on 4/23
Via Investor Brand Network
News headline image
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Heron Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>